Biogen (English Wikipedia)

"Sanofi buys US haemophilia treatment firm for $11.6 bn". Paris: AFP. January 22, 2018. Archived from the original on January 31, 2025. Retrieved January 31, 2025.

ft.com

markets.ft.com

"Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year – Company Announcement". Financial Times. 2021-11-15. Retrieved 2024-09-09.

genengnews.com

"Biogen Idec Snaps Up Convergence for Up-to-$675M - GEN News Highlights - GEN". 12 January 2015.

globenewswire.com

"Sanofi to Acquire Bioverativ for $11.6 Billion". January 22, 2018. Archived from the original on January 31, 2025. Retrieved January 31, 2025 – via Sanofi.

go.com

abcnews.go.com

"Health Highlights: August 1, 2008". ABC News. Retrieved 2021-09-11.
"Biogen will stop selling its controversial Alzheimer's drug Aduhelm". ABC News. Retrieved 2024-02-01.

ionispharma.com

ir.ionispharma.com

"Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders | Ionis Pharmaceuticals, Inc". ir.ionispharma.com. Retrieved 2021-10-05.

macrotrends.net

"Biogen Revenue 2006-2018 | BIIB". Macro Trends. Retrieved 2018-11-05.

miamitimesonline.com

Staff Report (9 September 2020). "Biotech company partners with Black-owned bank". The Miami Times. Retrieved 2020-09-13.

mstrust.org.uk

"Fampridine (Fampyra)". MS Trust.

multiple-sclerosis-research.blogspot.com

"Lingo: a promising remyelination target in MS". Multiple Sclerosis Research. Retrieved 2014-06-16.

nasdaq.com

"Biogen Idec Inc. Stock Quote & Summary Data". NASDAQ.

nationalmssociety.org

"Avonex". National MS Society.
"Tecifedra". National MS Society.
"Tysabri". National MS Society.

nbcboston.com

"3 Who Attended Biogen Meeting in Boston Test Positive for Coronavirus". NBC Boston. 5 March 2020. Retrieved 2020-03-09.
"Coronavirus Cases Linked to Biogen Boston Meeting: What We Know". NBC Boston. 6 March 2020. Retrieved 2020-03-09.

nobelprize.org

"Walter Gilbert". Nobel Prize. Retrieved June 3, 2024.
"Phillip A. Sharp". Nobel Prize. Retrieved June 3, 2024.

nytimes.com

Pollack, Andrew (24 June 2003). "Idec to Merge With Biogen in $6.8 Billion Deal". New York Times. Retrieved 2003-06-24.
Katie Thomas (31 December 2016). "Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval". The New York Times. Retrieved 2022-02-28.
Belluck, Pam; Kaplan, Sheila; Robbins, Rebecca (2021-07-20). "How an Unproven Alzheimer's Drug Got Approved". The New York Times. ISSN 0362-4331. Retrieved 2022-03-22.
Pam Belluck: F.D.A. Panel Declines to Endorse Controversial Alzheimer’s Drug. New York Times, November 6, 2020. Retrieved January 20, 2021.

nzz.ch

Werner Grundlehner: Zürcher Antikörper gegen Alzheimer hat Milliardenpotenzial – und Gegenwind. Neue Zürcher Zeitung, June 8, 2021. Retrieved June 8, 2021.

pharmatimes.com

"Biogen Idec agrees to buy Swiss company Fumapharm". Pharma Times. 2006-06-01. Retrieved 2017-12-28.

reuters.com

Mishra, Manas; Satija, Bhanvi; Satija, Bhanvi (2023-07-28). "Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio". Reuters. Retrieved 2023-07-28.
Pierson, Ransdell (2014-12-02). "Biogen plans late-stage Alzheimer's trial, shares rise". Reuters. Retrieved 2021-09-11.
Berkrot, Bill (2015-03-20). "Biogen's Alzheimer's drug slows mental decline in early study". Reuters. Retrieved 2021-09-11.
Steenhuysen, Julie; Beasley, Deena (2021-06-08). "U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients". Reuters. Retrieved 2021-10-11.
D'Souza, Savio (May 3, 2016). "Biogen to spin off hemophilia drug business into a public company". Reuters. Retrieved May 3, 2016.
Sudip Kar-Gupta (January 22, 2018). "Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion". Reuters. Archived from the original on January 31, 2025. Retrieved January 31, 2025.
"Companies in Alzheimer's race after US nod for Eisai/Biogen drug". Reuters.
"Biogen Idec's PLEGRIDY(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis". Reuters. Archived from the original on 2014-09-16. Retrieved 2017-06-30.
"UPDATE 1-Roche, Biogen end dispute over Rituxan follow-ons". Reuters. 21 October 2010. Archived from the original on 2014-07-27. Retrieved 2010-10-21.

sciencemag.org

Wadman, Meredith (23 December 2016). "Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease". Science. doi:10.1126/science.aal0476.

sec.gov

"Biogen, Inc. 2024 Annual Report". U.S. Securities and Exchange Commission. February 12, 2025.
"Biogen and IDEC Pharmaceuticals Announce Merger To Create a New Biotechnology Industry Leader". Exhibit 99.1. Retrieved 1 December 2018. IDEC — Founded in 1985 to develop monoclonal antibodies. Founders include Ivor Royston, Howard Birndorf, Richard Miller and Brook Byers
"Sanofi Completes Acquisition of Bioverativ Inc.- Bioverativ Inc. is a fully owned subsidiary of Sanofi". Paris. March 8, 2018. Archived from the original on January 31, 2025.

statista.com

"Biogen's revenue from 2007 to 2023". statista.com. Retrieved 23 May 2024.

statnews.com

"Biogen puzzles Wall Street with plans to spin off its hemophilia business". STAT. 2016-05-03. Retrieved 2021-10-05.
"Top Biogen execs were at meeting where attendees had Covid-19". STAT. 2020-03-06. Retrieved 2020-03-09.

thepharmaletter.com

"Biogen Idec's Eloctate gains FDA approval". The Pharma Letter. Retrieved 2014-09-06.
"Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis". The Pharma Letter.
"Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones". The Pharma Letter. Retrieved 2007-09-03.

tmx.com

money.tmx.com

"TMX Money". money.tmx.com. Retrieved 2021-10-05.

uci.edu

mind.uci.edu

Kirsten. "Investigational antibody treatment yields exciting though preliminary results - UCI MIND". Retrieved 2021-10-11.
Kirsten. "Phase 3 Trials of Aducanumab Halted - UCI MIND". Retrieved 2021-10-11.
Chelsea. "Biogen's About Face - UCI MIND". Retrieved 2021-10-11.

ucsd.edu

libraries.ucsd.edu

"The San Diego Technology Archive".

wbur.org

"Genetic 'Fingerprints' Suggest Superspreader Biogen Conference Seeded 40% Of Boston Coronavirus Cases". www.wbur.org. 25 August 2020. Retrieved 2021-09-27.

wcvb.com

"Workers who attended Boston Biogen meeting test positive for coronavirus". WCVB. 2020-03-06. Retrieved 2020-03-09.

web.archive.org

Reuters
Commissioner, Office of the (2021-06-07). "FDA Grants Accelerated Approval for Alzheimer's Drug". FDA. Archived from the original on June 7, 2021. Retrieved 2022-03-22.
"Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company - Biogen Media". Archived from the original on 2016-08-13. Retrieved 2016-08-11.
"Fortune 500 Companies 2021: Who Made the List". Fortune. Archived from the original on 2018-11-10. Retrieved 2022-02-08.
"FDA approves Gazyva for chronic lymphocytic leukemia". FDA. Archived from the original on November 2, 2013. Retrieved 2013-01-11.
"UPDATE 1-Roche, Biogen end dispute over Rituxan follow-ons". Reuters. 21 October 2010. Archived from the original on 2014-07-27. Retrieved 2010-10-21.
"FDA approves Rituxan to treat two rare disorders". FDA. Archived from the original on April 20, 2011. Retrieved 2011-04-19.
"FDA Grants Accelerated Approval for Alzheimer's Drug" (Press release). US Food & Drug Administration. 7 Jun 2021. Archived from the original on June 7, 2021. Retrieved 7 Jun 2021.

worldcat.org

search.worldcat.org

Belluck, Pam; Kaplan, Sheila; Robbins, Rebecca (2021-07-20). "How an Unproven Alzheimer's Drug Got Approved". The New York Times. ISSN 0362-4331. Retrieved 2022-03-22.
Grant, Charley (2016-12-27). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 2016-12-27.

wsj.com

Dulaney, Chelsey (23 March 2015). "Biogen Drops Idec From Name". Wall Street Journal. Retrieved 2015-03-23.
Grant, Charley (2016-12-27). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 2016-12-27.

xconomy.com

David Holley (July 2, 2015). "Biogen Offers Up To $1 Billion for AGTC's Ophthalmology Gene Therapy". Xconomy Boston.